Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harrison

Showing results (531-540 of 584) with videos related to

Pageof 59
Sort By:
Cancer|April 13, 2016
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study GroupHolly L Geyer, Bjorn Andreasson, Heidi E Kosiorek, et al.
Cancer Causes & Control : CCC|January 19, 2019
The Be-Well Study: a prospective cohort study of lifestyle and genetic factors to reduce the risk of recurrence and progression of non-muscle-invasive bladder cancerMarilyn L Kwan, Lawrence H Kushi, Kim N Danforth, et al.
Science (New York, N.Y.)|September 26, 2009
Distribution of mid-latitude ground ice on Mars from new impact cratersShane Byrne, Colin M Dundas, Megan R Kennedy, et al.
Hemasphere|March 25, 2025
Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health surveyClaire N Harrison, David M Ross, Laura Maria Fogliatto, et al.
NEJM Evidence|August 26, 2025
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> RearrangementSrdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.
The New England Journal of Medicine|February 12, 2015
Effect of mutation order on myeloproliferative neoplasmsChristina A Ortmann, David G Kent, Jyoti Nangalia, et al.
Journal of Hospital Medicine|February 22, 2024
Differences in testing for drugs of abuse amongst racial and ethnic groups at children's hospitalsAdriana Herrera, Matt Hall, Marshall Alex Ahearn, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 4, 2024
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY StudiesStacie Hudgens, Srdan Verstovsek, Lysbeth Floden, et al.
Lancet (London, England)|December 6, 2005
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyPeter J Campbell, Linda M Scott, Georgina Buck, et al.
Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.
Pageof 59

Showing results (531-540 of 584) with videos related to

Sort By:
Pageof 59
Cancer|April 13, 2016
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study GroupHolly L Geyer, Bjorn Andreasson, Heidi E Kosiorek, et al.
Cancer Causes & Control : CCC|January 19, 2019
The Be-Well Study: a prospective cohort study of lifestyle and genetic factors to reduce the risk of recurrence and progression of non-muscle-invasive bladder cancerMarilyn L Kwan, Lawrence H Kushi, Kim N Danforth, et al.
Science (New York, N.Y.)|September 26, 2009
Distribution of mid-latitude ground ice on Mars from new impact cratersShane Byrne, Colin M Dundas, Megan R Kennedy, et al.
Hemasphere|March 25, 2025
Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health surveyClaire N Harrison, David M Ross, Laura Maria Fogliatto, et al.
NEJM Evidence|August 26, 2025
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> RearrangementSrdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.
The New England Journal of Medicine|February 12, 2015
Effect of mutation order on myeloproliferative neoplasmsChristina A Ortmann, David G Kent, Jyoti Nangalia, et al.
Journal of Hospital Medicine|February 22, 2024
Differences in testing for drugs of abuse amongst racial and ethnic groups at children's hospitalsAdriana Herrera, Matt Hall, Marshall Alex Ahearn, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 4, 2024
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY StudiesStacie Hudgens, Srdan Verstovsek, Lysbeth Floden, et al.
Lancet (London, England)|December 6, 2005
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyPeter J Campbell, Linda M Scott, Georgina Buck, et al.
Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.
Pageof 59